Tiziana commences clinical trial of nasally administered Foralumab
Category: #health  By Saipriya Iyer  Date: 2020-11-04
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Tiziana commences clinical trial of nasally administered Foralumab

Tiziana Life Sciences, a biotechnology company, has reportedly commenced a collaborative clinical study of the nasally administered Foralumab. This fully human monoclonal antibody will be examined alone or in combination with orally-administered dexamethasone among COVID-19 infected patients in Brazil.

Considering the importance of developing an effective treatment for the COVID-19 disease, the team of scientists at Tiziana, Santa Casa de Misericórdia de Santos Hospital, and Harvard Medical School have formed a close partnership to facilitate the initiation of this clinical study in a limited time frame. In addition, the team at INTRIALS will coordinate the trial, with the results expected to be available by 2020 end.

As per the statement made by Dr. Kunwar Shailubhai, Tiziana Life Sciences’ CEO & CSO, there are nearly 5.5 million reported cases and 159,000 deaths from coronavirus in Brazil. The region is also experiencing over 1,000 death cases per day. The recently announced trial to activate nasal mucosal immunity by using Foralumab will significantly help curb the virus from infecting the lungs and respiratory tract.

The reduced and defective levels of Tregs (T regulatory) cells in the blood are expected to have a close connection with the high severity of ARDS (acute respiratory distress syndrome) and COVID-19. The nasal administration of Foralumab could potentially suppress excessive cytokine storm & hyperinflammation. These two conditions result in severe lung damage and respiratory failure, which are the main causes of morbidity and mortality among the COVID-19 patients.

Evidences from recently conducted clinical studies suggest that the peripheral Tregs level is observed to be significantly reduced among the severely infected COVID-19 patients. Moreover, the clinical data further indicated that the nasally administered Foralumab can stimulate the Tregs production in healthy volunteers. This demonstrates the importance of Foralumab in improving the clinical outcome of patients.

In addition, this highly innovative approach could be effectively used for the treatment of patients with other clinical conditions such as MERS (Middle Eastern Respiratory Syndrome) and SARS-CoV-1 (Severe Acute Respiratory Syndrome) due to its Tregs depletion capability.

Source credit:

https://www.biospace.com/article/releases/tiziana-announces-initiation-of-clinical-trial-with-covid-19-patients-in-brazil-with-nasally-administered-foralumab-a-fully-human-anti-cd3-monoclonal-antibody/



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...